KIMS Krishna Institute of Medical Sciences Q2 FY26 results (Jul–Sep 2025) and concall
KIMS reported a quarter of strong top-line growth driven by volume expansion and new facility commissioning, though consolidated margins faced significant pressure from the initial losses of 4-5 new hospitals. Management remains confident in a 12-month breakeven timeline for new assets, with Thane and Bangalore expected to lead the margin recovery. The core clusters in Telangana and Andhra Pradesh continue to deliver steady performance with sustainable margins in the 25-30% range.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q2 FY26: revenue up 18.5%, net profit down 11.1% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|
| Revenue | 363 | 348 | 346 | 373 | 430 +18% |
| EBITDA | 111 | 103 | 109 | 98 | 112 +1% |
| Net profit | 72 | 76 | 94 | 59 | 64 −11% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
